Brokerages Set InflaRx N.V. (NASDAQ:IFRX) Price Target at $7.00

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.00.

IFRX has been the subject of a number of research reports. Oppenheimer began coverage on shares of InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 target price for the company. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Cantor Fitzgerald raised their price target on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $7.00 to $9.00 in a research report on Wednesday, May 13th. Finally, HC Wainwright raised their target price on shares of InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, May 11th.

Hedge Funds Weigh In On InflaRx

Several institutional investors have recently made changes to their positions in IFRX. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of InflaRx in the first quarter valued at about $766,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of InflaRx in the second quarter valued at about $262,000. Squarepoint Ops LLC grew its holdings in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after purchasing an additional 42,489 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of InflaRx in the third quarter valued at about $214,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Stock Performance

Shares of InflaRx stock opened at $1.60 on Wednesday. The stock has a market capitalization of $115.66 million, a PE ratio of -2.25 and a beta of 2.42. InflaRx has a 52-week low of $0.74 and a 52-week high of $2.95. The company has a 50-day simple moving average of $1.88 and a two-hundred day simple moving average of $1.30.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. As a group, equities research analysts forecast that InflaRx will post -0.4 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.